Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 3—March 2025
Research
Model-Based Analysis of Impact, Costs, and Cost-Effectiveness of Tuberculosis Outbreak Investigations, United States
Sourya Shrestha
, Lucia Cilloni, Garrett R. Beeler Asay, J. Steve Kammerer, Kala Raz, Tambi Shaw, Martin Cilnis, Jonathan Wortham, Suzanne M. Marks, and David Dowdy
, Lucia Cilloni, Garrett R. Beeler Asay, J. Steve Kammerer, Kala Raz, Tambi Shaw, Martin Cilnis, Jonathan Wortham, Suzanne M. Marks, and David Dowdy
Table 5
Cost and cost-effectiveness (in 2022 US dollars) of TB outbreak investigation, United States, 2023–2037*
| Projected outcomes | Point estimate | Lower bound | Upper bound |
|---|---|---|---|
| Costs of genotyping, millions | $2.5 | $1.85 | $3.24 |
| Costs of outbreak investigation, millions | $135.0 | $46.6 | $251.0 |
| Costs of LTBI testing, millions | $49.0 | $17.7 | $84.4 |
| Costs of LTBI treatment, millions | $32.4 | $11.0 | $60.6 |
| Total cost, millions | $219.0 | $80.0 | $387.0 |
| Averted future costs of TB treatment, millions† |
($102.0) |
($29.7) |
($216.0) |
| QALYs gained by averted TB | 4,890 | 1,490 | 103,000 |
| QALYs gained by averted TB-related disabilities through early diagnosis | 183 | 51.4 | 4020 |
| Total QALYs gained | 5,070 | 1,560 | 106,000 |
| QALYs lost during LTBI treatment |
98.7 |
34.6 |
177.0 |
| Cost per QALY gained | $27,800 | $4,580 | $68,700 |
*The point estimate is the mean, and the lower and upper bounds represent the 2.5th and 97.5th percentiles across all 10,000 simulations. LTBI, latent TB infection; QLY, quality-adjusted life-years; TB, tuberculosis. †Future costs of treating future cases are discounted on the basis of their expected time of occurrence up to 5 years into the future.
Page created: January 17, 2025
Page updated: February 21, 2025
Page reviewed: February 21, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.